Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May 10;21(9):3378.
doi: 10.3390/ijms21093378.

Gender-Related Approach to Kidney Cancer Management: Moving Forward

Affiliations
Review

Gender-Related Approach to Kidney Cancer Management: Moving Forward

Mariangela Mancini et al. Int J Mol Sci. .

Abstract

Men are more frequently diagnosed with kidney cancer than women, with a more aggressive histology, larger tumors, a higher grade and stage, and worse oncological outcomes. Smoking habits and sex steroid hormones seem to have a possible role in explaining these gender disparities. Moreover, the expression of genes involved in tumor growth and immune response in kidney cancer varies between men and women, having an impact on the gender-related response to oncological therapy, such as anti-angiogenic drugs and immunotherapy. Recent advances have been made in our understanding of the molecular and genetic mechanisms involved in kidney cancer, which could partially explain the gender differences, and they are summarized in this paper. However, other key mechanisms, which fully clarify the striking clinical gender-related differences observed in kidney cancer, are not completely understood at present. We reviewed and summarized the most relevant publications about the relationship between gender and kidney cancer. Efforts should be made to progress in bench and clinical research on gender-related signatures and disparities, and their impact on the clinical management of kidney cancer.

Keywords: drug response and resistance; hormones profile and inflammation; kidney cancer; outcomes; renal cell carcinoma; sex and gender; sex-specific disease biomarkers.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., Rosso S., Coebergh J., Comber H., Forman D., Bray F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur. J. Cancer. 2013;49:1374–1403. doi: 10.1016/j.ejca.2012.12.027. - DOI - PubMed
    1. Capitanio U., Bensalah K., Bex A., Boorjian S.A., Bray F., Coleman J., Gore J.L., Sun M., Wood C., Russo P. Epidemiology of Renal Cell Carcinoma. Eur. Urol. 2019;75:74–84. doi: 10.1016/j.eururo.2018.08.036. - DOI - PMC - PubMed
    1. Dy G.W., Gore J.L., Forouzanfar M.H., Naghavi M., Fitzmaurice C. Global Burden of Urologic Cancers, 1990–2013. Eur. Urol. 2017;71:437–446. doi: 10.1016/j.eururo.2016.10.008. - DOI - PubMed
    1. Gelfond J., Al-Bayati O., Kabra A., Iffrig K., Kaushik D., Liss M.A. Modifiable risk factors to reduce renal cell carcinoma incidence: Insight from the PLCO trial. Urol. Oncol. Semin. Orig. Investig. 2018;36:340.e1–340.e6. doi: 10.1016/j.urolonc.2018.04.011. - DOI - PMC - PubMed
    1. Scelo G., Li P., Chanudet E., Muller D.C. Variability of Sex Disparities in Cancer Incidence over 30 Years: The Striking Case of Kidney Cancer. Eur. Urol. Focus. 2018;4:586–590. doi: 10.1016/j.euf.2017.01.006. - DOI - PubMed

Substances